Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reissue Patent
2007-01-09
2007-01-09
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S022100, C536S023100, C536S024300, C536S024310, C536S024320, C536S024330, C435S007200
Reissue Patent
active
10925348
ABSTRACT:
Novel chiral compounds that mimic and/or modulate the activity of wild-type nucleic acids are disclosed. In general, the compounds are phosphorothioate oligonucleotides wherein the 5′, and the 3′-terminal internucleoside linkages are chirally Sp and internal internucleoside linkages are chirally Rp.
REFERENCES:
patent: 3687808 (1972-08-01), Merigan et al.
patent: 4415732 (1983-11-01), Caruthers et al.
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4476301 (1984-10-01), Imbach et al.
patent: 4500707 (1985-02-01), Caruthers et al.
patent: 4668777 (1987-05-01), Caruthers et al.
patent: 4689320 (1987-08-01), Kaji
patent: 4725677 (1988-02-01), Koster et al.
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 4816571 (1989-03-01), Andrus et al.
patent: 4973679 (1990-11-01), Caruthers et al.
patent: 5004810 (1991-04-01), Draper
patent: 5023243 (1991-06-01), Tullis
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5132418 (1992-07-01), Caruthers et al.
patent: RE34069 (1992-09-01), Koster et al.
patent: 5166195 (1992-11-01), Ecker
patent: 5166315 (1992-11-01), Summerton et al.
patent: 5177196 (1993-01-01), Meyer et al.
patent: 5185444 (1993-02-01), Summerton et al.
patent: 5188897 (1993-02-01), Suhadolnik et al.
patent: 5194428 (1993-03-01), Agrawal et al.
patent: 5212295 (1993-05-01), Cook
patent: 5214134 (1993-05-01), Weis et al.
patent: 5216141 (1993-06-01), Benner
patent: 5235033 (1993-08-01), Summerton et al.
patent: 5242906 (1993-09-01), Pagano et al.
patent: 5248670 (1993-09-01), Draper et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5264562 (1993-11-01), Matteucci
patent: 5264564 (1993-11-01), Matteucci
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5278302 (1994-01-01), Caruthers et al.
patent: 5286717 (1994-02-01), Cohen et al.
patent: 5321131 (1994-06-01), Agrawal et al.
patent: 5399676 (1995-03-01), Froehler
patent: 5405938 (1995-04-01), Summerton et al.
patent: 5405939 (1995-04-01), Suhadolnik et al.
patent: 5434257 (1995-07-01), Matteucci et al.
patent: 5442049 (1995-08-01), Anderson et al.
patent: 5453496 (1995-09-01), Caruthers et al.
patent: 5455233 (1995-10-01), Spielvogel et al.
patent: 5457189 (1995-10-01), Crooke et al.
patent: 5466677 (1995-11-01), Baxter et al.
patent: 5470967 (1995-11-01), Huie et al.
patent: 5476925 (1995-12-01), Letsinger et al.
patent: 5489677 (1996-02-01), Sanghvi et al.
patent: 5506212 (1996-04-01), Hoke et al.
patent: 5512668 (1996-04-01), Stec et al.
patent: 5514577 (1996-05-01), Draper et al.
patent: 5514788 (1996-05-01), Bennett et al.
patent: 5519126 (1996-05-01), Hecht
patent: 5523389 (1996-06-01), Ecker et al.
patent: 5536821 (1996-07-01), Agrawal et al.
patent: 5541306 (1996-07-01), Agrawal et al.
patent: 5541307 (1996-07-01), Cook et al.
patent: 5550111 (1996-08-01), Suhadolnik et al.
patent: 5561225 (1996-10-01), Maddry et al.
patent: 5563253 (1996-10-01), Agrawal et al.
patent: 5571799 (1996-11-01), Tkachuk et al.
patent: 5580767 (1996-12-01), Cowsert et al.
patent: 5582972 (1996-12-01), Lima et al.
patent: 5582986 (1996-12-01), Monia et al.
patent: 5587361 (1996-12-01), Cook et al.
patent: 5591600 (1997-01-01), Ecker
patent: 5591623 (1997-01-01), Bennett et al.
patent: 5591720 (1997-01-01), Anderson et al.
patent: 5596086 (1997-01-01), Matteucci et al.
patent: 5599797 (1997-02-01), Cook et al.
patent: 5602240 (1997-02-01), De Mesmaeker et al.
patent: 5607923 (1997-03-01), Cook et al.
patent: 5608046 (1997-03-01), Cook et al.
patent: 5610289 (1997-03-01), Cook et al.
patent: 5618704 (1997-04-01), Sanghvi et al.
patent: 5620963 (1997-04-01), Cook et al.
patent: 5623070 (1997-04-01), Cook et al.
patent: 5625050 (1997-04-01), Beaton et al.
patent: 5633360 (1997-05-01), Bischofberger et al.
patent: 5658891 (1997-08-01), Draper et al.
patent: 5661134 (1997-08-01), Cook et al.
patent: 5663312 (1997-09-01), Chaturvedula
patent: 5670633 (1997-09-01), Cook et al.
patent: 5677437 (1997-10-01), Teng et al.
patent: 5677439 (1997-10-01), Weis et al.
patent: 5681747 (1997-10-01), Boggs et al.
patent: 5681944 (1997-10-01), Crooke et al.
patent: 5691461 (1997-11-01), Ecker et al.
patent: 5734041 (1998-03-01), Just et al.
patent: 6060456 (2000-05-01), Arnold, Jr. et al.
patent: 6111094 (2000-08-01), Bennett et al.
patent: 6242589 (2001-06-01), Cook et al.
patent: WO 94/08003 (1994-04-01), None
patent: WO 96/37504 (1996-11-01), None
patent: WO 96/39154 (1996-12-01), None
patent: WO 99/05160 (1999-02-01), None
Albert, P.R. et al., “Antisense knockouts:molecular scalpels for the dissection of signal transduction”, Trends Pharmacol. Sci., 1994, 15, 250-254.
Berkow et al. (eds.), The Merck, Manual of Diagnosis and Therapy, Rahway, N.J., 1987, 15th Edition, 2263-2277, 2283-2292, 2301-2310.
Bernhard et al., “Direct Evidence Linking Expression of Matrix Metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells,” Proc. Natl. Acad. Sci. USA, 1994, 91, 4293-4297.
Birkedal-Hansen, “Proteolytic Remodeling of Extracellular Matrix,”Curr. Op. Cell Biol.,1995, 7, 728-735.
Boggemeyer et al., “Borrelia Burgdorferi Upregulates the Adhesion Molecules E-selecin. P-Selectin. ICAM-1 and VCAM-1 on Mouse Endothelioma Cells in vitro.”Cell Adhes. Commun., 1994, 2, 145-157.
Cook, P.D., “Medicinal chemistry of antisense oligonucleotides—future opportunities”,Anti-Cancer Drug Design, 1991, 6, 585-607.
Crooke, S.T. et al., “Pharmacokinetic Properties of Several Novel Oligonucleotide Analogs in mice”,J. Pharmacol. Exp. Therapeutics, 1996, 277, 923-937.
Crooke, S.T. et al., “Progress in Antisense Oligonucleotide Therapeutic”,Ann. Rev. Pharmacol. Toxicol. 1996, 36, 107-129.
Dean, N.M. et al., “Inhibition of protein kinase C-αexpression in mice after systemic administration of posphorthioate antisense oligodeoxynucledotides”,Proc. Natl. Acad. Sci.,1994, 91, 11762-11766.
DeLisser et al., “Molecular and Functional Aspects of PECAM-1/CD31,”Immunol. Today, 1994, 15(10), 490-494.
Dimock et al., “An efficient multigram synthesis of monomers for the preparation of novel oligonucleotides containing isosteric non-phosphorous backbones”,Nucleosides&Nucleotides, 1997, 16(7-9), 1629-1632.
Downward, “The ras Superfamily of Small GTP-binding proteins,”TIBS,15, 1990, 469-472.
Englicsh, U. et al., “Chemically Modified Oligonucleotides as Probes and Inhibitors”,Angew. Chem. Int. Ed. Eng.,1991, 30, 613-629.
Griffiths, C.E.M. et al., “Keratinocyte Intercellular Adhesion Molecule-1 (ICAM-1) Expression Preceedes Derman T Lymphocyte Infiltration in Allegric Contact Dermatitis (Rhus dermatitis)”,Am. J. Pathology.,1989, 135, 1045-1053.
Gum et al., “Stimulation of 92-kDa Gelatinase B Promoter Activity by ras Is Mitogen-activated Protein Kinase Kinase 1-independent and Requires Multiple Transcription Factor Binding Sites Including Closely Spaced PEA3/ets and AP-1 Sequences,”J. Biol. Chem.,1996, 271(18), 10672-10680.
Guzavez et al., “Synthesis of14C-Radiolabeled Oligonucleotides with a Novel Phosphoramidite Reagent”,Bioorg. Med. Chem. Lett.1998, 8, 1123-1126.
Hakugawa et al., “The Inhibitory Effect of Anti-Adhesion Molecule Antibodies on Eosinophil Infiltration in Cutaneous Late Phase Response in Balb/c Mice Sensitized with Oval-bumin (OVA),”J. Dermatol.,1997, 24, 73-79.
Hegemann, L. et al. “Biochemical Pharmacology of Protein Kinase C and its Relevance for Dermatology”,Pharmacology of the Skin,Mukhtar, H. (ed.), CRC Press, Boca Raton, 1992, Ch.22, 357-268.
Himelstein et al., “Metalloproteinases in Tumor Progression: The Contribution of MMP-9,”Invasion&Metastsis,1994-95, 14, 246-258.
Ho, V.C. et al., “Treatment of severe lichen planus with cyclosporine”,J. Am. Acad. Dermatol.,1990, 22, 64-68.
Hua et al., “Inhibition of Matrix Metalloproteinase 9 Expression by a Ribozyme Blocks M
Cook Phillip Dan
Manoharan Muthiah
ISIS Patent Department Woodcock Washburn LLP
ISIS Pharmaceuticals Inc.
Owens, Jr. Howard V.
Wilson James O.
LandOfFree
Oligonucleolotides having site specific chiral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleolotides having site specific chiral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleolotides having site specific chiral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3823721